These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8618501)

  • 1. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease.
    Megnien JL; Levenson J; Simon A
    Lancet; 1996 Feb; 347(8999):468; author reply 468-9. PubMed ID: 8618501
    [No Abstract]   [Full Text] [Related]  

  • 2. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease.
    James MA
    Lancet; 1996 Feb; 347(8999):466; author reply 468-9. PubMed ID: 8618498
    [No Abstract]   [Full Text] [Related]  

  • 3. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease.
    Wierzbicki AS; Reynolds TM
    Lancet; 1996 Feb; 347(8999):466-7; author reply 468-9. PubMed ID: 8618499
    [No Abstract]   [Full Text] [Related]  

  • 4. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. GISSI-Prevenzione Investigators.
    Marchioli R; Bomba E; Tognoni G
    Lancet; 1996 Feb; 347(8999):467-8; author reply 468-9. PubMed ID: 8618500
    [No Abstract]   [Full Text] [Related]  

  • 5. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease.
    Haq IU; Jackson PR; Yeo WW; Ramsay LE
    Lancet; 1995 Dec; 346(8988):1467-71. PubMed ID: 7490996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of coronary heart disease through cholesterol reduction.
    Grundy SM
    Am Fam Physician; 1997 May; 55(6):2250-8. PubMed ID: 9149652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How sound are recommendations for lowering cholesterol for the primary prevention of coronary heart disease?
    Oliver MF
    Br J Clin Pract; 1993; 47(1):26-9. PubMed ID: 8461245
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of hypercholesterolemia with enzyme inhibitors].
    Valdés EF
    Medicina (B Aires); 1988; 48(4):425-8. PubMed ID: 3076202
    [No Abstract]   [Full Text] [Related]  

  • 11. Cholesterol and coronary heart disease: new data from the WOSCOP Study.
    Poli A
    Pharmacol Res; 1997 Mar; 35(3):171-2. PubMed ID: 9229403
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradox of cholesterol and stroke.
    Amarenco P; Steg PG
    Lancet; 2007 Dec; 370(9602):1803-4. PubMed ID: 18061038
    [No Abstract]   [Full Text] [Related]  

  • 14. [Maximal therapy of hypercholesterolemia in coronary heart disease].
    Thiery J; Armstrong V; Bosch T; Eisenhauer T; Schuff-Werner P; Seidel D
    Ther Umsch; 1990 Jun; 47(6):520-9. PubMed ID: 2375008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
    Gotto AM; Kuller LH
    Circulation; 2002 Jan; 105(2):136-9. PubMed ID: 11790688
    [No Abstract]   [Full Text] [Related]  

  • 16. Treating average cholesterol levels in patients with coronary heart disease.
    Lindbloom EJ
    J Fam Pract; 1999 Feb; 48(2):94-5. PubMed ID: 10037537
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comment from tHE cardiologic-angiologic viewpoint].
    Rosemann A
    Praxis (Bern 1994); 2011 Jul; 100(14):857-8. PubMed ID: 21732298
    [No Abstract]   [Full Text] [Related]  

  • 18. Towards a Paradigm Shift in Cholesterol Treatment. A Re-examination of the Cholesterol Issue in Japan.
    Hamazaki T; Okuyama H; Ogushi Y; Hama R
    Ann Nutr Metab; 2015; 66 Suppl 4():1-116. PubMed ID: 25925499
    [No Abstract]   [Full Text] [Related]  

  • 19. Lowering cholesterol levels in patients with coronary heart disease. The LIPID Study Management Committee.
    Med J Aust; 1995 May; 162(9):455-6. PubMed ID: 7746199
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
    Goldman L; Weinstein MC; Goldman PA; Williams LW
    JAMA; 1991 Mar; 265(9):1145-51. PubMed ID: 1899896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.